NEO-PV 01

Drug Profile

NEO-PV 01

Alternative Names: Neo Vax; NEO-PV-01; Neoantigen-based vaccine - Neon Therapeutics; NeoAntigen-peptides; Personalized-neoantigen-cancer-vaccine-Neon-Therapeutics

Latest Information Update: 23 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Broad Institute; Dana-Farber Cancer Institute
  • Developer Bristol-Myers Squibb; Dana-Farber Cancer Institute; Merck Sharp & Dohme; Neon Therapeutics
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Bladder cancer; Glioblastoma; Malignant melanoma; Non-small cell lung cancer

Most Recent Events

  • 01 Mar 2018 Phase-I clinical trials in Non-small cell lung cancer (Metastatic disease, Late-stage disease, Combination therapy, First-line therapy) in USA (Parenteral) (NCT03380871)
  • 14 Feb 2018 Washington University School of Medicine plans a phase I trial for Glioblastoma (Combination therapy, Newly diagnosed) in USA (NCT03422094)
  • 07 Dec 2017 Dana-Farber Cancer Institute plans a pilot phase I trial for Follicular lymphoma (Combination therapy, First-line therapy) in USA in December 2017 (NCT03361852)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top